Confluence Investment Management’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-136,359
Closed -$2.36M 300
2024
Q4
$2.36M Buy
136,359
+599
+0.4% +$11.6K 0.03% 169
2024
Q3
$2.52M Sell
135,760
-4,912
-3% -$98.6K 0.03% 170
2024
Q2
$2.85M Sell
140,672
-5,376
-4% -$95.1K 0.04% 164
2024
Q1
$2.49M Sell
146,048
-2,619
-2% -$41.2K 0.03% 172
2023
Q4
$2.63M Sell
148,667
-20,159
-12% -$406K 0.04% 174
2023
Q3
$4.05M Sell
168,826
-22,278
-12% -$547K 0.06% 146
2023
Q2
$4.44M Sell
191,104
-13,472
-7% -$305K 0.06% 143
2023
Q1
$4.51M Buy
204,576
+9,341
+5% +$219K 0.07% 148
2022
Q4
$3.96M Sell
195,235
-38,836
-17% -$753K 0.06% 160
2022
Q3
$3.15M Sell
234,071
-2,452
-1% -$41.3K 0.05% 164
2022
Q2
$4.69M Sell
236,523
-12,693
-5% -$337K 0.07% 148
2022
Q1
$7.88M Buy
249,216
+7,977
+3% +$224K 0.11% 121
2021
Q4
$5.38M Sell
241,239
-9,134
-4% -$238K 0.07% 145
2021
Q3
$6.95M Sell
250,373
-1,880
-0.7% -$57.2K 0.1% 127
2021
Q2
$9.82M Buy
+252,253
New +$9.04M 0.13% 111

Other funds holding CLB

Confluence Investment Management's CLB Position: Q1 2025 in Review

Confluence Investment Management sold out of Core Laboratories (CLB) in Q1 2025, closing a stake of 136,359 shares — an estimated $2.36M sold.

Confluence Investment Management first reported a position in CLB in Q2 2021 and held it in 15 quarters. The position peaked at $9.82M in Q2 2021. 195 funds tracked by Wall St. Rank hold CLB as of Q1 2025.

  • Confluence Investment Management reported no remaining Core Laboratories position as of Q1 2025 after selling out during the quarter.
  • Confluence Investment Management sold 136,359 Core Laboratories shares in Q1 2025, an estimated $2.36M.
  • Confluence Investment Management first reported a position in Core Laboratories in Q2 2021 and held it in 15 quarters.
  • Confluence Investment Management's Core Laboratories position peaked at $9.82M in Q2 2021.
  • 195 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2025.

Based on Confluence Investment Management's 13F filing for Q1 2025, filed 1 Apr 2025.